Journal
PEDIATRIC BLOOD & CANCER
Volume 59, Issue 4, Pages 642-647Publisher
WILEY PERIODICALS, INC
DOI: 10.1002/pbc.24004
Keywords
angiogenesis; extracellular signal-regulated MAP kinases; neuroblastoma; sorafenib
Categories
Funding
- Little Heroes Cancer Research Foundation
- Neuroblastoma Children's Cancer Society
- Super Jake Foundation
- Elise Anderson Neuroblastoma Research Fund
- St. Baldrick's Foundation Post-Doctoral Fellowship for Childhood Cancer Research
Ask authors/readers for more resources
Background More effective therapy for children with high-risk neuroblastoma is desperately needed. Preclinical studies have shown that neuroblastoma tumor growth can be inhibited by agents that block angiogenesis. We hypothesized that drugs which target both neuroblastoma cells and tumor angiogenesis would have potent anti-tumor activity. In this study we tested the effects of sorafenib, a multi-kinase inhibitor, on neuroblastoma cell proliferation and signaling, and in mice with subcutaneous human neuroblastoma xenografts or orthotopic adrenal tumors. Procedure Mice with subcutaneous neuroblastoma xenografts or orthotopic adrenal tumors were treated with sorafenib, and tumor growth rates were measured. Blood vessel architecture and vascular density were evaluated histologically in treated and control neuroblastoma tumors. The in vitro effects of sorafenib on neuroblastoma proliferation, cell cycle, and signaling were also evaluated. Results Sorafenib inhibited tumor growth in mice with subcutaneous and orthotopic adrenal tumors. Decreased numbers of cycling neuroblastoma cells and tumor blood vessels were seen in treated versus control tumors, and the blood vessels in the treated tumors had more normal architecture. Sorafenib treatment also decreased neuroblastoma cell proliferation, attenuated ERK signaling, and enhanced G1/G0 cell cycle arrest in vitro. Conclusions Our results demonstrate that sorafenib inhibits the growth of neuroblastoma tumors by targeting both neuroblastoma cells and tumor blood vessels. Single agent sorafenib should be evaluated in future phase II neuroblastoma studies. Pediatr Blood Cancer 2012;59:642647. (c) 2011 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available